Kyverna Therapeutics, Inc. (KYTX) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Gilead Sciences, Inc. entity

10% owner

$20.02M (1)

—

+$20.02M

4,126,119

6.67%

$30.95M

—

Bain Capital Life Sciences Investors, LLC entity

10% owner

$9.90M (1)

—

+$9.90M

3,163,868

5.12%

$23.73M

—

Northpond Ventures III GP, LLC entity

Former 10% Owner

$9.90M (1)

—

+$9.90M

450,000

0.7276%

$3.38M

—

Vida Ventures, LLC entity

10% owner

$5.57M (2)

—

+$5.57M

583

0.0009%

$4.37K

—

Beth C Seidenberg

Director

$1,000.00K (1)

—

+$1,000.00K

891,044

1.44%

$6.68M

—

Westlake BioPartners Opportunity Fund I, L.P. entity

10% owner

$1,000.00K (1)

—

+$1,000.00K

869,317

1.41%

$6.52M

+18.1%

Karen Marie Walker

Chief Technology Officer

—

$292.78K (1) scheduled

−$292.78K

22,636

0.0366%

$169.77K

—

Fred E Cohen

Director

—

4,545,651

7.35%

$34.09M

—

Westlake BioPartners Fund I, L.P. entity

10% owner

—

735,984

1.19%

$5.52M

—

Christi Shaw

Executive Chairperson

—

66,741

0.1079%

$500.56K

—

Warner Weston Biddle

Chief Executive Officer

—

58,000

0.0938%

$435.00K

—

Ryan Alexander Jones

Chief Financial Officer

—

55,950

0.0905%

$419.63K

+115.7%

Ian T Clark

Director

—

21,727

0.0351%

$162.95K

—

Mert Aktar

Director

—

21,727

0.0351%

$162.95K

—

Naji Gehchan

See Remarks

—

18,000

0.0291%

$135.00K

—

Daniel K Spiegelman

Director

—

16,634

0.0269%

$124.76K

—

Sravan Kumar Emany

Director

—

11,006

0.0178%

$82.55K

—

Andrew Craig Miller

Director

—

11,006

0.0178%

$82.55K

—

Marc Grasso

Chief Financial Officer

—

10,000

0.0162%

$75.00K

—

Kyverna Therapeutics, Inc.

What the insiders did Net buying

By person